Stoke Therapeutics Business Summary

Stoke Therapeutics, Inc. (STOK) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing and collaboration agreements, notably with Biogen and Acadia Pharmaceuticals, while advancing its proprietary pharmaceuticals pipeline. The company’s business model is centered on its Targeted Augmentation of Nuclear Gene Output (TANGO) platform, which utilizes antisense oligonucleotides (ASOs) to upregulate protein expression for treating haploinsufficiency-related genetic disorders. Its primary business segments are focused on the clinical development of lead assets, including zorevunersen (STK-001) for Dravet syndrome, currently in Phase 3 trials, and STK-002 for Autosomal Dominant Optic Atrophy (ADOA). Direct competitors include WaVe Life Sciences, Kymera Therapeutics, and Vaxcyte; Stoke distinguishes itself as a specialized leader in RNA-based protein upregulation, bridging the gap between traditional gene therapy and standard ASO-mediated knockdown approaches. The company was co-founded by Dr. Isabel Aznarez, who serves as Senior Vice President and Head of Research, and Dr. Adrian Krainer, a renowned pioneer in RNA splicing from Cold Spring Harbor Laboratory and a member of the Board of Directors. The leadership team is headed by CEO Ian F. Smith, a veteran biotech executive and former CFO/COO of Vertex Pharmaceuticals, alongside CFO Thomas E. Leggett and Chief Medical Officer Dr. Barry S. Ticho. Stoke is supported by a robust roster of institutional investors, including BlackRock, FMR LLC (Fidelity), and RTW Investments, and its Board is chaired by Dr. Arthur Tzianabos, former CEO of Homology Medicines.